Patents by Inventor Kyung Sun Kang

Kyung Sun Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240098091
    Abstract: Provided is a method performed by a least one computing device for a message service. The method comprises receiving a transmission request for a compound message which is a bundled message comprising a parent message and a plurality of child messages, obtaining permission information for a sender of the compound message, determining whether to allow each of the child messages to be sent based on the permission information and controlling transmission of the compound message based on the determination result.
    Type: Application
    Filed: July 5, 2023
    Publication date: March 21, 2024
    Applicant: SAMSUNG SDS CO., LTD.
    Inventors: Myoung Kyhun CHOI, Han Eol LEE, Kyung sun KANG, Yong Kook PARK, Ki Man KIM
  • Publication number: 20240075072
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, containing, as an active ingredient, stem cells overexpressing SOD3. The present inventor has ascertained that mesenchymal stem cells (MSCs) overexpressing SOD3 have a stronger antioxidant activity and immune regulatory function than normal MSCs, and thus the MSCs overexpressing SOD3 can be an effective treatment agent for inflammatory diseases, autoimmune diseases, organ transplant rejection and the like.
    Type: Application
    Filed: June 14, 2023
    Publication date: March 7, 2024
    Inventors: Kyung Sun Kang, Tae Yoon Kim
  • Patent number: 11912674
    Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: February 27, 2024
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
  • Publication number: 20230405185
    Abstract: The present invention relates to a composition for preparing a decellularized scaffold, including nano graphene oxide. The present inventors crosslinked nano graphene oxide to a decellularized liver scaffold to strengthen the properties of the scaffold and suppress protease activity of the scaffold, and thus have established an optimum crosslinking condition exhibiting the effects of anti-inflammation and polarization to M2 macrophages. That is, since it is confirmed that nano graphene oxide strengthens the durability of the scaffold so that biodegradation is suppressed and, simultaneously, inflammatory responses that may occur after transplantation are minimized, it is expected that nano graphene oxide can be effectively used in the production and transplantation of clinically applicable artificial organs.
    Type: Application
    Filed: November 16, 2021
    Publication date: December 21, 2023
    Inventors: Kyung-Sun KANG, Da-Hyun KIM, Jaechul RYU
  • Publication number: 20230392127
    Abstract: Provided is a method for constructing an atopic dermatitis skin organoid from human pluripotent stem cells. It was observed that ALI-skin organoids of the presently claimed subject matter formed skin cells, appendages, neural cells, adipocytes, and the like in similar structures to those in the real skin and exhibited greatly improved follicle growth, compared to skin organoids constructed by existing culture methods. In addition, as a result of treatment with Staphylococcus aureus to construct an atopic dermatitis model, a good simulation was made of the characteristics of atopic dermatitis, such as damaged skin barriers, increased epithelium-derived cytokines and downregulated epidermal stem cell expression, causing Staphylococcus aureus colonies, and the like. Thus, the skin organoid of the presently claimed subject matter is expected to find advantageous applications as a real skin model and an atopic dermatitis model.
    Type: Application
    Filed: October 21, 2021
    Publication date: December 7, 2023
    Applicant: KANGSTEM BIOTECH CO., LTD.
    Inventors: Kyung-Sun KANG, Song-Yi JUNG
  • Patent number: 11786549
    Abstract: The present invention relates to an anti-inflammatory composition comprising a graphene nano-structure as an active ingredient. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease, and a cosmetic composition or feed composition for preventing or improving an inflammatory disease, which include the anti-inflammatory composition, and a method of treating an inflammatory disease, including administering the composition to a subject in need thereof.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: October 17, 2023
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, BIOGRAPHENE INC.
    Inventors: Kyung-Sun Kang, Byung-Chul Lee, Jin Young Lee, Jong Bo Park
  • Publication number: 20230321153
    Abstract: The present invention relates to a method of manufacturing an animal cartilage-derived injectable composition, an injectable composition manufactured by the method, and a use thereof. The injectable composition of the present invention includes a collagen-containing biomaterial in a formulation injectable into joint cavity and may induce cartilage tissue regeneration by repairing tissue via direct injection to a target region without surgical incision. In addition, the injectable composition may be used as a therapeutic agent for arthritis by alleviating osteoarthritis not only because the animal cartilage-derived extracellular matrix contained in the injectable composition protects articular cartilage tissue but also because an environment capable of regenerating damaged articular tissue is created by inducing differentiation of intra-articular stem cells into chondrocytes.
    Type: Application
    Filed: June 13, 2023
    Publication date: October 12, 2023
    Inventors: Kyung Sun Kang, Seunghee Lee, Jong Chan Ahn, Mijin Kim
  • Publication number: 20230285635
    Abstract: Provided is a method for producing highly functional artificial organs, including blood vessels capable of carrying perfusate, by using aptamers. The aptamers, according to the presently claimed subject matter, enhance blood vessel adhesion ability, viability, angiogenesis potential, and the like when used as a coating agent of a decellularized scaffold, and thus can more efficiently reconstruct vasculature than existing antibodies. Therefore, a vascularized artificial liver produced using the aptamers exhibits the effects of reducing thrombogenesis in vivo as well as enhancing liver function, and thus is expected to be applied as a method for treating diseases by using artificial organs produced using the aptamers according to the presently claimed subject matter.
    Type: Application
    Filed: July 27, 2021
    Publication date: September 14, 2023
    Applicant: KANGSTEM BIOTECH CO., LTD.
    Inventors: Kyung-Sun KANG, Da-Hyun KIM
  • Patent number: 11730766
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, containing, as an active ingredient, stem cells overexpressing SOD3. The present inventor has ascertained that mesenchymal stem cells (MSCs) overexpressing SOD3 have a stronger antioxidant activity and immune regulatory function than normal MSCs, and thus the MSCs overexpressing SOD3 can be an effective treatment agent for inflammatory diseases, autoimmune diseases, organ transplant rejection and the like.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 22, 2023
    Inventors: Kyung Sun Kang, Tae Yoon Kim
  • Publication number: 20230051601
    Abstract: Disclosed is a method for producing a stem cell with enhanced efficacy, a stem cell produced thereby, and a method for treating a disease using the same. According to the present invention, sizes of stem cells may be reduced and proliferation ability, differentiation potency, migration ability, and angiogenic potential of stem cells may be significantly enhanced by applying a culturing method provided herein. Thus the present invention may be usefully applied to development of therapeutic agents using stem cells.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 16, 2023
    Inventors: Mijin Kim, Jong Chan Ahn, Seunghee Lee, Kwang-won Seo, Kyung-sun Kang
  • Patent number: 11512285
    Abstract: The present invention relates to a method of preparing induced neural stem cells which are reprogrammed from differentiated cells. The method of producing the induced neural stem cells according to the present invention enables preparation of the induced neural stem cells from non-neuronal cells using only two inducing factors of SOX2 and HMGA2. Therefore, the method of the present invention can prepare induced neural stem cells in a more efficient manner than the conventional methods, which use four or five inducing factors. Additionally, the method of the present invention shows significantly higher inducing efficiency and proliferation capacity than when only a single SOX2 gene is used, thus increasing its potency to be used for therapeutic purposes.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: November 29, 2022
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, KANGSTEM BIOTECH CO., LTD.
    Inventors: Kyung Sun Kang, Kyung Rok Yu
  • Publication number: 20220096540
    Abstract: Provided is a method for prevention or treatment of a lysosomal storage disorder, and more particularly, to a method that may exhibit excellent efficacy against various lysosomal storage disorders including Niemann-Pick disease by including graphene quantum dots.
    Type: Application
    Filed: January 23, 2020
    Publication date: March 31, 2022
    Applicants: BIOGRAPHENE INC., SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION
    Inventors: Kyung-Sun KANG, Byung Hee HONG, Insung KANG, Je Min YOO, Donghoon KIM
  • Publication number: 20210254005
    Abstract: The present disclosure relates to a differentiation totipotent stem cell having suppressed immune rejection, by having expression of Beta-2 microglobulin (B2M) gene suppressed, and expressing Cluster of Differentiation 24 (CD24), immune cell, and pharmaceutical composition including the same.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 19, 2021
    Applicant: KANGSTEM BIOTECH CO., LTD.
    Inventors: Kyung-Sun KANG, Daekee KWON, Mi-Jung HAN, Seunghee LEE
  • Publication number: 20210222127
    Abstract: Provided are a method of preparing induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), both having a reduced expression level of HLA, which is a cause of immune rejection upon transplantation of cells, tissues, or organs, a method of preparing mesenchynmal stem cells (MSCs) by using a novel differentiation method of iPSCs, and a cell therapy product using the iPSCs, ESCs, and/or MSCs. The HLA gene-deleted MSCs prepared in the present invention may be used to prepare various types of cells that do not cause immune rejection, and may be used for therapeutic purposes in the future.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 22, 2021
    Inventors: Kyung-Sun Kang, Kwang Won Seo, Hee-Jin Ahn, Daekee Kwon, Mi-Jung Han
  • Publication number: 20200360429
    Abstract: The present invention relates to an anti-inflammatory composition comprising a graphene nano-structure as an active ingredient. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease, and a cosmetic composition or feed composition for preventing or improving an inflammatory disease, which include the anti-inflammatory composition, and a method of treating an inflammatory disease, including administering the composition to a subject in need thereof.
    Type: Application
    Filed: November 23, 2018
    Publication date: November 19, 2020
    Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, BIOGRAPHENE INC.
    Inventors: Kyung-Sun KANG, Byung-Chul LEE, Jin Young LEE, Jong Bo PARK
  • Patent number: 10584312
    Abstract: The present invention relates to a method for isolating pluripotent/multipotent stem cells derived from umbilical cord blood, characterized by culturing mononuclear cells isolated from umbilical cord blood in a culture vessel containing fibronectin and then harvesting stem cells from the culture, the umbilical cord blood-derived pluripotent/multipotent stem cells isolated thereby; and a cell therapeutic agent containing the pluripotent/multipotent stem cells derived from umbilical cord blood or cells differentiated therefrom. The present invention also relates to a novel culture media for stem cells, a culture method for stem cells which is characterized by culturing and proliferating stem cells in the culture media, and a method for increasing sternness of stem cells which is characterized by a sphere culture or a three-dimensional culture of stem cells.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: March 10, 2020
    Assignee: SNU R&DB FOUNDATION
    Inventors: Kyung Sun Kang, Kyoung Hwan Roh
  • Publication number: 20190365820
    Abstract: The present invention relates to a complex for promoting cartilage differentiation comprising stem cells or a culture thereof and a cartilage cell-free crush, a method for fabricating cartilage by using the complex, cartilage fabricated via the method, a pharmaceutical composition comprising the complex for preventing or treating arthropathy, a method for preventing or treating arthropathy using the composition, a composition for inducing cartilage cell differentiation comprising the prepared cartilage cells, and a method for fabricating cartilage using the prepared cartilage cells.
    Type: Application
    Filed: July 4, 2017
    Publication date: December 5, 2019
    Inventors: Kyung Sun Kang, Kwang Won Seo, Kyung Ae Yoon, Hyo Jin Jeon, Yun Beom Sim
  • Publication number: 20190133922
    Abstract: The present invention relates to exosomes with an increased amount of growth factors, which are obtained from stem cells cultured in a medium containing an epithelial growth factor (EGF) and/or a fibroblast growth factor (FGF). It is expected that the nano-sized exosomes isolated from a stem cell culture liquid can penetrate into the dermal layer of the skin and thereby increase their regenerative effect. In addition, since exosomes contain a large amount of various growth factors, they provide effects such as skin regeneration and anti-aging, promotion of collagen synthesis, hair growth, restoration of shrunken hair follicles, and wound healing through proliferation and activation of fibroblasts, which are skin component cells.
    Type: Application
    Filed: January 12, 2017
    Publication date: May 9, 2019
    Inventors: Kyung Sun KANG, Kwang Won SEO, Yu Lee KIM, Yoon Jin KIM
  • Publication number: 20190111108
    Abstract: Provided are a pharmaceutical composition for regenerating skin, a pharmaceutical composition for improving wrinkles, a pharmaceutical composition for treating wounds, a quasi-drug composition for regenerating skin, a quasi-drug composition for improving wrinkles, a quasi-drug composition for treating wounds, a cosmetic composition for regenerating skin, a cosmetic composition for improving wrinkles, a cosmetic composition for improving wounds, and a medium composition for culturing fibroblasts, each composition including GDF11 or a human-derived adult stem cell culture medium including the same, a method of culturing fibroblasts by using the medium composition, and a method of preparing GDF11 by culturing stem cells.
    Type: Application
    Filed: December 2, 2016
    Publication date: April 18, 2019
    Inventors: Yoon Jin Kim, Seung Hee Lee, Kwang Won Seo, Kyung Sun Kang
  • Publication number: 20180344774
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, containing, as an active ingredient, stem cells overexpressing SOD3. The present inventor has ascertained that mesenchymal stem cells (MSCs) overexpressing SOD3 have a stronger antioxidant activity and immune regulatory function than normal MSCs, and thus the MSCs overexpressing SOD3 can be an effective treatment agent for inflammatory diseases, autoimmune diseases, organ transplant rejection and the like.
    Type: Application
    Filed: September 19, 2016
    Publication date: December 6, 2018
    Inventors: Kyung Sun Kang, Tae Yoon Kim